Medical News Today: Guanfacine vs. Adderall: What is the difference?

0
32

Doctors prescribe the two drugs guanfacine and Adderall for attention deficit hyperactivity disorder, which people more often call ADHD. These medications work in different ways and have different side effects. Learn about both here, how to take them, and which one may be more suitable.

Related Links:

THURSDAY, Aug. 27, 2020 — Young adults who’ve had attention-deficit/hyperactivity disorder (ADHD) since childhood are at increased risk for road crashes, researchers say.
But there is no increased risk for those whose ADHD symptoms have decreased,…

This study tests the effectiveness of parent-teen psychotherapy for adolescent ADHD (Supporting Teens ’ Autonomy Daily; STAND) versus Usual Care (UC) in four community clinics.

Co-occurring psychiatric disorders in adults with Attention Deficit Hyperactivity Disorder (ADHD) and/or Autism Spectrum Disorder (ASD) contribute to the burden of the healthcare and possibly to the delay of d…

Source: BMC PsychiatryCategory: Psychiatry Authors: Tags: Research article Source Type: research

AbstractLoss-of-function variants inCREBBP orEP300 result in Rubinstein –Taybi syndrome (RSTS). The previously reported cluster of variants in the last part of exon 30 and the beginning of exon 31 ofCREBBP, overlapping with the ZNF2 (zinc finger, ZZ-type; residues 1701 to 1744) and ZNF3 (zinc finger, TAZ-type; residues 1764 to 1853) domains, is associated with atypical RSTS. The main features include developmental delay, short stature, microcephaly, distinctive facial features, autistic behavior, feeding difficulties, recurrent upper airway infections, and hearing impairment. Here, we report a 2-year-7-month-old Chin…

ConclusionsElectroencephalogram can have a use in clinical settings to aid adult attention deficit hyperactivity disorder diagnosis, but areas of inconsistency are apparent.

Publication date: Available online 23 August 2020Source: Journal of Psychiatric ResearchAuthor(s): Rachel F.L. Walsh, Brooke Sheppard, Lihong Cui, Cortlyn Brown, Anna Van Meter, Kathleen R. Merikangas

Our understanding of neuropsychiatric disorders has gained tremendous progress with the advancement of genetics studies, both in establishing the high heritability for these classes of disorders and through the identification of specific genetic associations (1). Large-scale genetic studies —both rare-variant, family-based studies and common variant, genome-wide association studies (GWASs)—have uncovered the genetic architecture of neuropsychiatric disease and implicate common variants as the largest contributor to disease liability for the majority of these disorders, including au tism spectrum disorder (ASD),…

Source: Biological PsychiatryCategory: Psychiatry Authors: Tags: Commentary Source Type: research

Although stimulant medications for attention-deficit/hyperactivity disorder (ADHD) have been used for many decades and are recommended in clinical guidelines, they have been the target of many media campaigns that decry their effectiveness and raise alarms about adverse effects, despite substantial evidence to the contrary from double-blind randomized controlled trials (RCTs) (1). The dissemination of misinformation about medications for ADHD is far from benign. It creates stigma and diverts parents and patients from evidence-based treatments to less effective or ineffective alternatives (2).

Source: Biological PsychiatryCategory: Psychiatry Authors: Tags: Commentary Source Type: research

Conclusions Current results provide important evidence for the construct of APD. The MAPA-2 can be administered by an audiologist or speech-language pathologist. A similar diagnostic protocol in Australia yielded positive therapeutic gains. Further study is encouraged to determine if the present positive findings will be found in future research.
PMID: 32831000 [PubMed – as supplied by publisher]

Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here